D. E. Shaw & Co., Inc. Ventyx Biosciences, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 89,380 shares of VTYX stock, worth $206,467. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,380
Previous 196,114
54.42%
Holding current value
$206,467
Previous $1.08 Million
80.89%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VTYX
# of Institutions
124Shares Held
57.4MCall Options Held
222KPut Options Held
269K-
Deerfield Management Company, L.P. (Series C) New York, NY5.83MShares$13.5 Million0.28% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.76MShares$13.3 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA5.25MShares$12.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$11 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.32 Million0.04% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $131M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...